Lipoxins (LXs) are trihydroxytetraene-containing arachidonic acid mediators that down-modulate and promote the resolution of infl ammatory processes ( 1 -7 ) . LXs play a key counterregulatory role in mouse models of infection with Mycobacterium tuberculosis and Toxoplasma gondii ( 1 -3, 7 ) . Similarly, defi cient LX-mediated counterregulation has been linked to the pathogenesis of infl ammatory diseases, such as severe asthma ( 8 ) , cystic fi brosis lung disease ( 3 ) , and periodontal disease ( 7 ) . The benefi cial eff ects of LX analogue administration in diverse rodent models of infl ammatory pathology, along with the observation that administration of the widely used antiinfl ammatory drug ASA leads to the generation of metabolically more stable LX carbon 15-epimers (ASA-triggered LX [ATL]), has suggested therapeutic promise for specifi c harnessing of the biological activities of these potent lipid mediators. However, their molecular mechanisms of action remain underdefi ned.
We recently showed that suppressor of cytokine signaling (SOCS) 2 is a crucial intracellular mediator of the antiinfl ammatory actions of LX and ATL in vivo during T. gondii infection ( 9 ) . SOCS proteins are known to inhibit receptor-mediated signal transduction via several pathways, including inhibition of tyrosine phosphorylation by allosteric blockage (e.g., of JAK proteins) and induction of proteasomal degradation through promoting polyubiquitylation (e.g., of STAT proteins) ( 10 ) . Our studies were aimed at defi ning the molecular targets and mechanisms of action of LX-and ATL-induced SOCS2. The results presented in this study demonstrate that LX and ATL induce SOCS2-dependent ubiquitinylation and proteasomal degradation of TNF receptor -associated factor (TRAF) 2 and TRAF6, inhibiting DC production of proinfl ammatory cytokines. 
RESULTS

LX-induced SOCS2 physically interacts with TRAF2 and TRAF6
Given that LX-induced SOCS2 is a physiological modulator of Toll-like receptor (TLR) -dependent innate immune recognition of T. gondii , we examined whether LX-induced SOCS2 interacted specifi cally with conserved signaling elements Further, these results indicate that the proteosome-dependent pathway of modulating innate immune signaling aff ected by LX and ATL is critical for restraining in vivo infl ammatory responses during infection with T. gondii . Our fi ndings elucidate a previously unappreciated mechanism of action of ASA, and suggest a new molecular target for drug development for diseases caused or exacerbated by dysregulated infl ammatory responses. (A) Splenic DCs were incubated with 1 μ g/ml LXA 4 or 100 ng/ml IL-10 or media control (CT) for 6 or 12 h. SOCS2 or SOCS1 was immunoprecipitated (I.P.) from whole-cell lysates, followed by Western blot analysis of immunoprecipitates and total cell lysates to quantify SOCS1, SOCS2, TRAF1-6, IRAK4, MyD88, and actin expression. (B) DCs from WT or SOCS2-defi cient mice were exposed to 1 μ g/ml LXA 4 or vehicle for 6 h, followed by stimulation with IL-1 ␤ , TNF (both at 100 ng/ml), CD40L, STAg, LPS, or CpG-oligonucleotides (all at 1 μ g/ml). 4 h later, mRNA was purifi ed and real-time RT-PCR was used to quantify TNF, IL-6, IL-12p40, and IFN-␣ mRNA expression. Data shown are the mean ( ± the SD) of triplicate samples, and are representative of at least two independent experiments with similar results. Asterisks indicate statistically signifi cant differences between SOCS2-defi cient and WT control mice (P < 0.05). ( 11 -13 ) . TRAF2 and TRAF6 regulate the transcription of downstream target genes via activation of the c-Jun N-terminal kinase (JNK) and NF-B signaling pathways ( 14 -19 ) . Notably, TRAF6-defi cient mice fail to produce IL-12 in response to microbial stimuli ( 19 ) . To examine the functional consequences of LXA 4 -stimulated SOCS2 -TRAF interactions during DC activation, WT and SOCS2-defi cient mouse splenic DCs were downstream of the TLRs. Purified splenic DCs ( ‫ف‬ 90% CD11c + ) were incubated with LXA 4 (or IL-10, which activates SOCS1 and SOCS3, as a control), and coimmunoprecipitation techniques were used to defi ne specifi c interactions of TLR signaling intermediates with SOCS1 and SOCS2. As shown in Fig. 1 A , immunoprecipitation of SOCS2, but not SOCS1, from LXA 4 -treated DCs led to specifi c coprecipitation of TRAF6 and TRAF2, but not MyD88, IRAK4, or any of the other TRAFs. This specifi city among TRAFs is notable. SOCS interacts with SH2 domains on other proteins ( 10 ) , which are present on all members of the TRAF family. WT and SOCS2-defi cient splenic DCs were treated with LXA 4 (at concentrations ranging from 10 to 1,000 ng/ml) for 20 h, or were treated with LXA 4 or IL-10 (at 100 ng/ml times ranging from 1 to 20 h), followed by quantifi cation of TRAF6 and actin expression by Western blot. (B) DCs from WT and SOCS2-defi cient mice were treated with 2 μ M lactacystin or medium alone, 1 h before incubation with 1 μ g/ml LXA 4 . At the indicated times, whole-cell extracts were prepared and TRAF2, TRAF6, ERK2, p38, JNK2, I B ␣ , and actin expression was quantifi ed by immunoblot analysis. (C) DCs from WT and SOCS2-defi cient mice were incubated with 1 μ g/ml LXA 4 . At the indicated times, whole-cell extracts were immunoprecipitated with antibodies to ubiquitin, TRAF2, or TRAF6, followed by Western blot analysis using antibodies to TRAF2, TRAF6, or polyubiquitin (clone FK1). (D) WT and SOCS2-defi cient DCs were treated with 2 μ M lactacystin or vehicle for 1 h. DCs were subsequently incubated with 1 μ g/ml LXA 4 or vehicle for 8 h, followed by stimulation with 100 ng/ml STAg for 24 h. IL-12 p70 levels were quantifi ed by ELISA in culture supernatants. Data shown represent the means ± the SD of triplicate samples and are representative of at least two independent experiments with similar results. *, P < 0.01, PBS versus inhibitor treatment. ( Fig. 2 C ) . Thus, as might be expected, biochemical inhibition of proteasome activity with lactacystin led to parallel ablation of both LX-induced, SOCS2-dependent TRAF2/6 degradation and LX-induced, SOCS2-dependent inhibition of TLR-driven cytokine production in DCs ( Fig. 2, B and D ) . The fact that treatment of SOCS2-defi cient DCs with lactacystin failed to alter TRAF levels and IL-12 production ( Fig. 2, B and D ) suggests little toxicity for this inhibitor under these conditions. Collectively, these data suggest that these LX-mediated antiinfl ammatory actions are dependent on SOCS2-induced TRAF2 and TRAF6 proteasomal degradation.
TRAF6 in DCs
Restoration of TRAF6 expression overcomes LX-mediated modulation of myeloid cell cytokine production To directly defi ne the roles of TRAF2 and TRAF6 as downstream targets for LX-mediated antiinfl ammatory activity, we analyzed the ability of LXA 4 to inhibit IL-12 and TNF production in response to TLR or TNFR stimulation after overexpression of TRAF2, TRAF3, or TRAF6 in a mouse macrophage cell line (RAW264.7). As shown in Fig. 3 A , TRAF2 and TRAF6 overexpression overcame LX-dependent degradation. Only overexpression of TRAF6, but not TRAF2 or 3, reversed LX-induced inhibition of IL-12 and TNF production after TNFR/TLR stimulation ( Fig. 3 Thus, SOCS2-mediated degradation of TRAF6 is essential to LX-mediated inhibition of proinfl ammatory cytokine production. treated with LXA 4 and stimulated with IL-1 ␤ , TNF, CD40L, LPS, CpG-oligonucleotides, or soluble T. gondii tachyzoite antigen (STAg). Exposure to LXA 4 strongly blocked the expression of IL-6, TNF-␣ , IL-12, and IFN-␣ in WT but not SOCS2-defi cient DCs, regardless of the stimulus ( Fig. 1 B ) . Thus, LX-induced SOCS2 inhibits biological responses known to be dependent on TRAF2/6, suggesting that these adaptors are functional targets of SOCS2-dependent modulation of proinfl ammatory responses.
SOCS2 targets TRAF2 and TRAF6
for proteasomal degradation SOCS proteins mediate their actions by docking to the intracellular domains of pattern recognition, cytokine, or hormone receptors (thereby preventing interactions with downstream signaling elements), or by ubiquitinylation and proteasomedependent degradation of signaling intermediates ( 10, 20 -22 ) . To analyze the latter possibility, we quantifi ed the stability of TRAF2/6 in LXA 4 -exposed (or IL-10 -exposed) DCs. As shown in Fig. 2 (A and B) , exposure to LXA 4 , but not IL-10, led to a SOCS2-dependent reduction in the amount of TRAF2 and TRAF6 protein expression as early as 5 h after exposure, whereas the expression levels of related signaling intermediates, including ERK2, JNK2, p38, and I B ␣ were not altered. Notably, LXA 4 exposure led to SOCS2-dependent polyubiquitylation of TRAF2 and TRAF6 ( Fig.  2 C ) . Also, it is important to note that the reciprocal immune precipitation of TRAF2/6, followed by Western blot for polyubiquitin chain, revealed a similar pattern of LXinduced SOCS2-dependent polyubiquitylation of TRAF2 and starting at day 11, which was previously found to be the time at which increases in serum levels of LXA 4 are detectable. At this time point, most T cell priming is thought to have occurred. Moreover, direct testing of the eff ect of proteasome inhibition on CD8 + T cell during LCMV infection showed that such treatment did not aff ect expansion of CD8 + T cells specifi c for LCMV-derived peptides ( To assess the in vivo relevance of LX-induced, SOCS2-dependent TRAF6 proteasomal degradation, we moved to an in vivo model of LX-dependent inhibition of DC IL-12 production, termed " DC paralysis " ( 23 ) . In this system, injection of STAg causes endogenous generation of LXA 4 that, in turn, inhibits IL-12 production by DCs during subsequent rechallenge ( Fig. 4 A ) . As noted previously, DC paralysis is SOCS2-dependent; SOCS2-defi cient mice produce equivalent amounts of IL-12 regardless of previous STAg challenges ( Fig. 4 A ) ( 9 ) . Importantly, mice treated with lactacystin or another proteasome inhibitor, PR-11 ( 24 ) , failed to exhibit DC paralysis, producing equivalent levels of IL-12 as single STAg-injected WT mice ( Fig. 4 A ) . Moreover, neither lactacystin nor PR11 treatment aff ected IL-12 production in STAg-injected SOCS2-defi cient mice, excluding the possibility of unrelated nonspecifi c eff ects after in vivo proteasome inhibition. IL-10 -defi cient mice suff er acute mortality caused by uncontrolled infl ammation during T. gondii infection ( 25 ) . The induction of DC paralysis rescues IL-10 -defi cient mice from such mortality ( 25 ) . Notably, pretreatment with the proteasome inhibitor PR11 before DC paralysis ablated the protective eff ects of STAg-induced DC paralysis in IL-10 -defi cient mice ( Fig. 4 B ) . Thus, the protective actions of LX-stimulated DC paralysis during T. gondii infection are mediated in a proteasome-dependent manner that correlates with SOCS2-driven proteasome-mediated degradation of TRAF6.
In vivo proteasome inhibition abolishes the antiinfl ammatory actions of LX-stimulated SOCS2: modulation of proinfl ammatory responses during infection Endogenously generated LXs control proinfl ammatory responses through SOCS2 during T. gondii and M. tuberculosis infection ( 2, 26 ) . In the absence of LXs or SOCS2, infection with T. gondii is lethal because of aberrant, uncontrolled infl ammation ( 26 ) . To analyze whether proteasomal degradation of TRAF2 and TRAF6 are downstream targets for LX-mediated control of proinfl ammatory responses during in vivo infection, we infected WT and SOCS2-defi cient mice with T. gondii , in the presence or absence of treatment with PR11 reversed by PR11 treatment ( Fig. 5 G The benefi cial biological eff ects of in vivo ASA administration occur, in part, through the generation of endogenous ATL. Our data at this juncture suggested that ATL-stimulated, SOCS2-mediated, proteasome-dependent degradation of TRAF proteins is mechanistically important for ASA-driven modulation of proinfl ammatory cytokine production. Indeed, similar to the eff ects of LXA 4 exposure, in vivo exposure of DCs to ASA led to SOCS2-independent ATL generation ( Fig. S10 A, available at http://www.jem.org/cgi/content/ full/jem.20072416/DC1), along with a SOCS2-dependent specifi c decrease in DC expression of TRAF6 and TRAF2 ( Fig. 6 A ) . LPS treatment alone did not change baseline levels of signaling molecules either in WT or SOCS2-defi cient DCs, except for the expected decrease in I B ␣ ( Fig. 6 A ) ( 24 ) . ASA treatment before LPS exposure delayed the appearance of phosphorylated ERK1/2 and p38 in WT, but not in SOCS2-defi cient, DCs ( Fig. 6 A ) . Consistent with fi ndings in cells exposed to ASA alone, TRAF2 and TRAF6 expression was decreased in LPS-stimulated, ASA-treated WT, but not SOCS2-defi cient, DCs. Finally, LPS-induced I B ␣ degradation was prevented by ASA treatment in a SOCS2-dependent manner ( Fig. 6 A ) . Although the cause-eff ect relationship is likely to be indirect, the delay in the generation of 15-epi-LX in aspirin (ASA)-treated, COX1-defi cient mice indicated that both SOCS2 induction and TRAF6 degradation are dependent on the endogenous generation of 15-epi-LX ( Fig. 6 B ) . As indicated, although both WT and SOCS2-defi cient DCs generated signifi cant levels of 15-epi-LX after ASA treatment, COX1-defi cient mice presented a signifi cant delay with low levels of the eicosanoid (Fig. S10 B) . This fi nding suggests that COX1-derived prostanoids are required to establish the enzymatic pathways needed to produce 15-epi-LXA 4 , rather than direct involvement of COX1 in the biosynthesis of 15-epi-LXA 4 in this system (for review see [ 7 ] ). ASA caused a SOCS2-dependent ablation of LPSinduced TNF and IL-12p70 production ( Fig. 6 C ) , suggesting that ATL-induced SOCS2 regulates the LPS-driven signaling cascade in DCs by inhibiting I B ␣ degradation and abolishing NF-B signaling. In agreement with these observations, in vivo treatment with ASA led to TRAF2/TRAF6 polyubiquitylation and degradation that could be prevented by pretreatment with PR11 ( Fig. 6, D and E ) . Such treatment (c) mortality occurring ‫ف‬ 45 -50 d after inoculation ( Fig. 5 F ) . Interestingly, we found higher frequencies of IFN-␥ -producing CD4 + and CD8 + T cells after in vitro recall stimulation ( Fig. 5, C and D ) , supporting our fi ndings that proteasome inhibition not only did not inhibit T cell priming during infection, but enhanced it. Immunofl uorescence analysis revealed that SOCS2-dependent loss of TRAF2 and TRAF6 expression in spleen and brain during T. gondii infection was WT and SOCS2-defi cient mice ( n = 10 mice/group) were treated orally with ASA (5 mg/kg), or PBS as a control. 45 min later, splenic DCs were purifi ed and stimulated with LPS (1 μ g/ml) or medium alone. At the indicated times, TRAF2, TRAF6, ERK2, p38, JNK2, I B ␣ , pJNK, pERK1/2, pP38, and actin expression were quantifi ed as indicated in Fig. 2 . (B) Splenic DCs purifi ed from WT, SOCS2-defi cient, and COX1-defi cient mice were incubated in the absence or presence of 5 mM ASA for 0, 30, or 90 min, followed by quantifi cation of actin, TRAF6, and SOCS2 expression by Western blot. (C) Splenic DCs, purifi ed from WT and SOCS2-defi cient mice that had been treated with ASA or PBS as in A, were stimulated with LPS (1 μ g/ml) or PBS. After overnight culture, IL-12p70 and TNF secretion was quantifi ed in by ELISA. (D) Splenic DCs purifi ed from WT and SOCS2-defi cient mice that had been treated with ASA or PBS as in A underwent Western blot analysis of polyubiquitylated TRAF2 and TRAF6, as indicated in Fig. 2 . (E and F) WT and SOCS2-defi cient mice were injected intraperitoneally with 0.2 mg/Kg PBS or PR11, followed by PBS or ASA treatment. 1 h later, splenic DCs were purifi ed and whole-cell extracts underwent immunoblot analysis to quantify TRAF2 and TRAF6 expression (E). WT and SOCS2-defi cient mice were injected intraperitoneally with PR11 (or PBS), followed by ASA (or PBS). 45 min later, mice were challenged intraperitoneally with LPS (5 μ g/mouse). tors such as the TLRs ( 28 -31 ) , responding by secreting cytokines important in immune activation and specifi cation of the class of immune response. During infection with T. gondii (and infection with diverse other intracellular pathogens), DC production of IL-12, IFN-␥ , and TNF is essential in controlling pathogen growth ( 32 -34 ) . IL-12 and TNF are potentially toxic when produced in excess, and their production is known to be carefully regulated by a remarkably large number of diff erent mechanisms ( 26, 29, 32 ) . In toxoplasmosis, the proinfl ammatory process is counterbalanced by the simultaneous induction of critical, nonredundant counterregulatory mediators, including IL-10 and LXs ( 32, 33 ) . Mice with a genetic defi ciency in LX production succumb to lethal infl ammatory responses during toxoplasmosis. In turn, the biological importance and nonredundant nature of the proteasome pathway to the mechanism of action of LXs is underscored by the fi nding that proteasome inhibition during toxoplasmosis prevents the regulatory actions of LX, restoring TLR and cytokine receptor signaling in vivo and causing uncontrolled proinfl ammatory cytokine production, aberrant leukocyte infi ltration and elevated mortality. Since its fi rst chemical synthesis and clinical trials in the late 19th century, the cellular and molecular mechanisms of action of ASA have been the focus of intense research ( 35 ) . In the early 1970s, a series of reports by J.R. Vane established that ASA and ASA-like drugs inhibit prostaglandin synthesis ( 36 ) . For the next 20 yr, this was the dominant view for the overall mechanism of action of ASA, despite the fi nding that at the cellular level, ASA inhibits neutrophil activation, even in the presence of cyclooxygenase products ( 37 ). Claria and Serhan ( 38 ) showed that, in the presence of ASA, cyclooxygenase-2 is acetylated, yet remains active and converts arachidonic acid into intermediates that are converted into potent ATL, thus opening the possibility that ATLs are indeed mediating the antiinfl ammatory actions of ASA in vivo. Indeed, ATLs display powerful pro-resolution and antiinfl ammatory actions in several cell types and disease settings ( 27 ) . This new body of evidence sheds light on the possible intracellular pathways that are controlled by ASA and ATLs. ASA has been shown to inhibit neutrophil and macrophage activation, calcium fl ux, and integrin activation, as well as IL-12, TNF, and IL-8 production ( 27 ) , suggesting that the downstream inhibition targets are critical elements of a general proinfl ammatory pathway. In agreement with this hypothesis, it was shown that ASA blocks NF-B activation and nuclear translocation ( 39 ) . Our earlier observation that ATL-induced SOCS2 mediated some of the antiinfl ammatory actions of ASA (9) opened the possibility of exploring novel intracellular mechanisms of action of this drug. The results presented in this study clearly indicate that TRAF6 is a key molecular target of ASA and that proteasome-mediated degradation of TRAF6 plays an important role and is a major infl ammation resolution pathway up-regulated by ASA. In a similar vein, Paul-Clark et al. recently demonstrated that 15-epi-LXA 4 mediates ASA induction of nitric oxide, negatively regulating leukocyte-endothelium interactions ( 40 ) . What role this also abolished SOCS2-dependent inhibition of in vivo LPSinduced TNF production ( Fig. 6 F ) and thioglycollate-stimulated neutrophil migration (Fig. S10, C and D) .
To further evaluate ATL-induced, SOCS2-mediated inhibition of NF-B activation, we correlated NF-B localization with DNA-binding activity. As shown in Fig. 6 (G -O) , LPS treatment caused nuclear translocation of NF-B p65, something prevented by ASA pretreatment in a SOCS2-dependent manner. NF-B p65 DNA-binding activity paralleled its nuclear translocation ( Fig. 6 O ) ; similar fi ndings were obtained for NF-B p50 (Fig. S11 , available at http://www .jem.org/cgi/content/full/jem.20072416/DC1). Thus, the antiinfl ammatory eff ects of ASA on DCs is mediated by SOCS2-dependent proteasomal degradation of TRAF2/TRAF6.
DISCUSSION
Immunologists have traditionally focused on the mechanisms that underlie and control the activation of infl ammatory responses. The last decade has seen growing awareness and experimental attention paid to the fact that restraint and resolution of infl ammatory responses is also, perforce, under tight, active regulation. In turn, this has led to growing interest in facilitation of resolution (as opposed to inhibition of activation) as a therapeutic strategy for the dysregulated infl ammation seen as central to the pathogenesis and expression of an increasingly wide spectrum of diseases ( 27 ) . Therapeutic harnessing of the multilevel, resolution-promoting bioactivities of the LXs, and novel resolution mediators such as the D-and E-series resolvins and protectins, is thus quite attractive.
The mechanisms of action of the LXs, at the level of cellular signaling, are of interest. Along these lines, LXA 4 and ATL restrain innate and acquired immune responses via stimulating SOCS2 expression in an AhR-dependent manner ( 9 ) . The current studies elucidate new molecular targets and mechanism of action of LX/ATL-induced SOCS2. Specifically, these results indicate that: (a) LX-induced SOCS2 targets TRAF2 and TRAF6 for proteasomal degradation; (b) degradation of TRAF6 renders cells exposed to LX unable to respond to stimulation through TLRs, TNF-R, IL-1R, and CD40, resulting in the inhibition of proinfl ammatory cytokine production by DCs; (c) proteasome-mediated degradation of TRAF6 plays a major role in the mechanism of action of ASA in restraining DC production of proinfl ammatory cytokines; and (d) this pathway of targeted proteasomal degradation of signaling intermediates is critical for successful modulation of infl ammatory responses during infection with the ubiquitous protozoan pathogen, T. gondii . The biological role of LX-and ASA-driven TRAF2 degradation remains to be defi ned.
A fundamental question in host -pathogen interactions is whether the immune system is properly activated to eradicate the pathogens, and whether this response is appropriately controlled to prevent damage to the host during control or elimination of infection. Microbial recognition is a critical fi rst step. Central to both innate and adaptive immunity, DCs signal the presence of microbes via pattern recognition recep-DNA transfection. 10 7 RAW 264.7 (or HL60) cells were transfected as previously described ( 42 ) with 10 μ g of mTRAF6 (Invivogen), fl ag-tagged mTRAF2, fl ag-tagged mTRAF3, or the respective control plasmids. To determine transfection effi ciency, all cells were also transfected with pMaxGFP plasmid (Amaxa). Cells were then plated in 24-well plates in RPMI (supplemented with 10% FCS, l-glutamine, and gentamycin). 20 h after transfection, cells were exposed to LXA 4 or vehicle control and incubated for a further 24 h before stimulation with LPS, CD40L, TNF, or STAg. Cells and supernatants were harvested 24 h after stimulation and analyzed for GFP expression (FACS), IL-12 expression (ELISA), and expression of the transfected proteins (Western blot).
Statistical analysis. The statistical signifi cance of diff erences in mean values between experimental versus control or vehicle-treated samples was evaluated by means of Student ' s t test. Diff erences were considered to be significant at P < 0.05.
Online supplemental material. Fig. S1 shows that TRAF2 and TRAF6 are molecular targets for LX-mediated, SOCS2-dependent inhibition of TLR and TNFR family signaling. Fig. S2 shows that late in vivo treatment with PR11 during LCMV infection does not aff ect the priming of LCMVspecifi c CD8+ T cells. Fig. S3 shows the cytokine expression in the presence of proteasome inhibition during infection with T. gondii . Figs. S4-9 shows the in situ immunofl uorescence analysis of SOCS2 induction, TRAF2 and TRAF6 expression, and pro-infl ammatory gene expression after proteasome inhibition during T. gondii infection of WT and SOCS2-defi cient mice. It has become clear in recent years that dysregulated infl ammatory responses are central to the pathogenesis of a wide range of diseases, causing an enormous burden of morbidity and mortality in the world at large. The results presented in this study suggest that degradation of TRAF6 provides a promising biochemical target for drug development aimed at modulating infl ammatory processes in these diseases.
MATERIALS AND METHODS
Animals. WT C57BL/6 mice were obtained from The Jackson Laboratory. C57BL/6, SOCS2-KO, and IL-10-KO were bred and maintained under pathogen-free conditions at the Cincinnati Children ' s Hospital Medical Center (CCHMC) animal facility. All experimental protocols were approved by the CCHMC Institutional Animal Care and Use Committee. Animals were infected by intraperitoneal injection with 20 cysts of T. gondii cysts (ME49 strain) recovered from brain homogenates from chronically infected mice. STAg was prepared from sonicated tachyzoites, as previously described ( 41 ) .
Cytokine quantifi cation. IL-12 p70 (BD Biosciences), TNF-␣ , and IFN-␥ secretion was quantifi ed using commercial ELISA kits (R & D Systems). For in vitro experiments, splenic DCs were partially purifi ed, as previously described ( 29 ) . Cytokine concentrations in supernatants were normalized to foldchanges, based on the ratio of values in experimental to baseline samples. It is important to note that baseline cytokine secretion by naive DCs did not diff er signifi cantly among the diff erent genetic backgrounds (WT vs. SOCS2 KO) used in these studies. 4 . Mice or culture DCs were treated with ASA (in vivo or in vitro, respectively), and the 15-epi-LXA 4 was quantifi ed in urine or supernatants, respectively, using commercial ELISA kit (Neogen Corp.).
15-epi-LXA
Microscopy. Spleens and brains were removed from mice before or 30 d after infection, and frozen sections were processed and stained with a goat antimouse SOCS2, goat anti -mouse TNF, goat anti -mouse p50 or p65, rabbit anti -mouse TRAF2 or TRAF6, and rabbit anti -mouse iNOS (all from Santa Cruz Biotechnologies), followed by a double incubation with Alexa Fluor 488 -conjugated anti -mouse CD11c (Caltag), or Alexa Fluor 488 -conjugated anti -rabbit and Alexa Fluor 594 -conjugated anti -goat antibodies (Invitrogen), as previously described ( 23 ) . The cells were counterstained for nuclei with DAPI (Invitrogen). For in situ TRAF2, TRAF6, p50, and p65 analysis, we isolated DCs (purity: ‫ف‬ 90% CD11c + cells), stimulated them as described for each experiment, and fi xed them with ice-cold acetone for 1 min and processed and stained as described above. Images were acquired using a microscope (Axiovert; Carl Zeiss, Inc.) with the AxioVision software (Carl Zeiss, Inc.) Measurement of p50 and p65. Nuclear extracts were purifi ed, and p50 and p65 binding activity was quantifi ed using Transcription Factor Assay kits according to the manufacturer ' s instructions (ActiveMotif).
Cell extracts and immunoblots. Whole-cell extracts were generated by lysing WT and SOCS2-defi cient DCs in buff er containing 50 mM Hepes, pH 7.9, 0.25 M NaCl, 5 mM EDTA, 0.1% NP-40, 1 mM PMSF, and 1X HALT protease inhibitor cocktail (Thermo Fisher Scientifi c). For detection of phosphorylated-proteins, Na 3 VO 4 and NaF were added to lysis buff ers. Immunoprecipitation was performed with SOCS2 antibody obtained from Santa Cruz Biotechnology, Inc. The detection of protein expression by Western blot was performed with primary antibodies against SOCS2, SOCS1, TRAF1-6, IRAK4, MyD88, ERK2, P38, JNK2, I B ␣ , pJNK, and pERK1/2, all obtained from Santa Cruz Biotechnology Inc. Anti-phospho-SAPK/JNK and anti-phospho-p38 antibodies were purchased from Cell Signaling Technology, and anti-JNK/SAPK1 was purchased from Millipore.
